Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News

Blood pressure graphic | Image Credit: © Dzianis Vasilyeu-stock.adobe.com
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score

April 8th 2025

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.

PAH | Image Credit: © Richelle-stock.adobe.com
Burden of PAH Weighs Heavy Worldwide

April 4th 2025

Glass pharmaceutical vials | Image credit: ronnarong – stock.adobe.com
Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH

March 31st 2025

Pulmonary hypertension | Image Credit: © Uladzislau-stock.adobe.com
PAH Therapies Improve Outcomes in PH-ILD

March 26th 2025

Hypertension | Image Credit: © jeffy1139-stock.adobe.com
Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials

March 24th 2025

More News

Human heart beats: © Sergey Nivens - stock.adobe.com
June 10th 2023

More Evidence Needed to Clarify the Role of Right Heart Imaging in PAH

Gianna Melillo
Results are based on a series of surveys completed by 17 experts.
image of healthy food
June 9th 2023

Digital Approach to Nutritional Education May Improve Nutritional Intake, Boost QOL in Patients With PAH

Gianna Melillo
The pilot program for pulmonary arterial hypertension (PAH) was carried out at a single center in the Netherlands.
A female doctor sits at her desk and chats to an elderly female patient while looking at her test results: © lordn - stock.adobe.com
May 23rd 2023

Disconnect Exists Between PAH Study Outcomes and Patients’ Priorities

Jared Kaltwasser
Patients who have pulmonary arterial hypertension (PAH) often do not feel better after treatment, even if they meet clinical endpoints for improvement.
Two human hands are holds human lungs. Support healthy lungs concept. Wireframe glowing low poly design on dark blue background. Abstract futuristic vector illustration: © Elena - stock.adobe.com
May 18th 2023

Patients With PAH Face Unique Considerations for Lung Transplantation

Jaime Rosenberg
Pulmonary arterial hypertension (PAH) is the only major diagnostic indication for transplantation that is not a parenchymal pulmonary process.
ICER to Review Sotatercept for Pulmonary Arterial Hypertension
May 15th 2023

ICER to Review Sotatercept for Pulmonary Arterial Hypertension

Allison Inserro
If approved by the FDA, sotatercept would be the first therapy that acts directly against the cause of the disease.
doctor hands holding lungs organ , world tuberculosis day, world no tobacco day, lung cancer, Pulmonary hypertension, copd, eco air pollution, pneumonia, donation, respiratory and chest concept: © Kiattisak - stock.adobe.com
May 5th 2023

Research Explores Causes Behind Ineffective NO Treatment for Hypoxic Pulmonary Hypertension

Gianna Melillo
Researchers set out to examine the effects of sodium nitroprusside on the thromboxane-mediated contraction and nitric oxide (NO)-independent relaxation pathways and on reactive oxygen species accumulation in pulmonary artery smooth muscle cells.
Doctor measuring blood pressure to pregnant woman: © bernardbodo - stock.adobe.com
May 1st 2023

Children of Mothers With HDP Have Greater Risk of Overall, Specific High Refractive Error

Jaime Rosenberg
A Danish study of nationwide registries estimated a 39% greater risk of high refractive error among children of mothers with hypertensive disorder of pregnancy (HDP), a complication that affects 5% to 10% of pregnancies.
Word cloud for Vasodilation: © intheskies - stock.adobe.com
April 24th 2023

Pulmonary Vasodilator Treatment May Lower Hospitalization Risk From SAPH

Jaime Rosenberg
These insights represent the first characterization of risk factors for respiratory failure–related hospitalization among patients with sarcoidosis‐associated pulmonary hypertension (SAPH).
Human lungs anatomy form lines and triangles, point connecting network on blue background. Illustration vector: © pickup - stock.adobe.com
April 22nd 2023

Case Report of Novel Variant in Patient With PAH Highlights Benefit of Genetic Testing

Jaime Rosenberg
Subsequent testing revealed the presence of the variant in the patient’s siblings, also underscoring the importance of counseling family members who have pulmonary arterial hypertension (PAH).
Blue stamp on a glittering background: quality of life: © Argus - stock.adobe.com
April 17th 2023

PEA Leads to Long-term QOL Improvement in People With CTEPH, Study Suggests

Jared Kaltwasser
Most patients with chronic thromboembolic pulmonary hypertension (CTEPH) said they can go about their daily activities without restriction, the authors found, because of gains in functional status and quality of life (QOL).
Lungs. Lung problems on light blue background: © Tom - stock.adobe.com
April 10th 2023

Patients With PAH Accrue Higher Costs, HRU, Regardless of Etiology

Jaime Rosenberg
Patients with pulmonary arterial hypertension (PAH) related to connective tissue disorders (CTDs) and patients with PAH related to another condition accrued higher costs and higher health care resource use (HRU) vs patients who had CTD without PH.
In the hand are paper sick lungs: © Asha Natasha - stock.adobe.com
March 31st 2023

Parameter Trio Can Help Predict Prognosis in Children With PAH

Jaime Rosenberg
Although they note that their risk combination model needs validation, investigators argue that their insights should guide recommendations for risk stratification and management of these patients.
Image of a right ventricle straining: Rasi - stock.adobe.com
March 18th 2023

Study Underscores Need for Optimal RV Function Measures in PH

Jaime Rosenberg
Right ventricular (RV) dysfunction has previously been linked to symptoms and mortality in pulmonary hypertension (PH), as well as in other conditions, and RV function plays an important role in disease risk and potentially in intensification of pulmonary arterial hypertension treatment.
Stylized lung representation: pickup - stock.adobe.com
March 11th 2023

Noninvasive Predictors of Pulmonary Hypertension in Interstitial Lung Disease Identified

Jaime Rosenberg
The researchers noted that their study is the first to assess the ability of noninvasive variables, both resting- and exercise-based, to identify pulmonary hypertension in interstitial lung disease.
Data for Therapies to Treat Cholesterol, PAH Highlight ACC Scientific Sessions
March 2nd 2023

Data for Therapies to Treat Cholesterol, PAH Highlight ACC Scientific Sessions

Mary Caffrey
The 72nd American College of Cardiology Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC), runs from Saturday to Monday in New Orleans, Louisiana.
Graphic representing a person exercising
February 25th 2023

Impaired Exercise Capacity From PAH-CHD Most Prominent in Patients With Eisenmenger Syndrome

Jaime Rosenberg
Study findings offer insight into how exercise intolerance varies among subgroups of pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), as previous data have characterized impaired exercise tolerance among PAH-CHD as a whole.
Image demonstrating use of artificial intelligence
February 24th 2023

Novel Machine Learning Model May Detect Pulmonary Hypertension Earlier

Jaime Rosenberg
Having a diagnostic model that leverages artificial intelligence could fill a gap in the pulmonary hypertension (PH) diagnostic pathway, as there are currently just 2 validated screening algorithms for PH.
Image representing a diagnosis
February 6th 2023

Nationwide Data Show Delayed Correct Diagnosis for PAH

Jaime Rosenberg
The long time to diagnosis is consistent with data pointing to pulmonary arterial hypertension (PAH) often being misdiagnosed as asthma, said the researchers, adding that the findings from their retrospective study provide valuable insight into where the diagnostic pathway lags.
researcher looking into microscope
January 27th 2023

Researchers Find 4 Biomarkers Linked to Copper Metabolism in PAH

Hayden E. Klein
The 4 biomarkers linked to copper metabolism in pulmonary arterial hypertension (PAH) were DDIT3, NFKBIA, OSM, and PTGER4.
pregnant woman holding stomach
January 19th 2023

Fetal Outcomes, Maternal Mortality Vary Among Pregnant Women With Different Types of PH

Hayden E. Klein
A small study conducted in China suggests pregnant women with idiopathic pulmonary arterial hypertension (iPAH) are at higher risk of maternal mortality compared with women with certain other types of pulmonary hypertension (PH).
Woman coughing
January 9th 2023

Contraction, Mortality Rate of COVID-19 Was Lower in Vaccinated Patients With PAH

Julia Bonavitacola
Patients with pulmonary arterial hypertension (PAH) were more likely to die or be hospitalized if they contracted COVID-19 but were less likely to die from COVID-19 if they were vaccinated against SARS-CoV-2.
Macitentan box
January 6th 2023

Macitentan for PAH Associated With Cost-effectiveness, Higher Total QALYs

Julia Bonavitacola
This new study from Iran investigated outcomes following treatment for pulmonary arterial hypertension (PAH) with macitentan compared with bosentan.
Top 5 graphic for PAH content
December 31st 2022

Top 5 Most-Read PAH Content of 2022

Maggie L. Shaw
The most-read articles in pulmonary arterial hypertension (PAH) for this year ran the gamut of special-interest areas: from treatment costs to pediatric PAH to high-risk patients.
Image of a stethoscope
December 21st 2022

Hemodynamic Improvement Seen From Combo Treatment for PoPH

Maggie L. Shaw
For this analysis, the Japan Pulmonary Hypertension Registry provided data from 2008 to 2021 on patients with diagnosed portopulmonary hypertension (PoPH).
Image of a sick child
December 4th 2022

TPS Improves PAH Functional Outcomes in a Pediatric Population

Maggie L. Shaw
The study investigators wanted more data on long-term outcomes in pediatric patients following implantation of a transcatheter Potts shunt (TPS) for treatment of severe pulmonary arterial hypertension (PAH).
Image of a blood pressure gauge
November 22nd 2022

Remote BP, Cholesterol Management Effective, but Patient Engagement Could Be Better

Maggie L. Shaw
Researchers investigated outcomes following implementation of remote care that targeted effective control of hypertension, or elevated blood pressure (BP), and cholesterol management.
Image of postgraduate medical training
November 17th 2022

Hypertension Knowledge, Training Lacking Within Internal Medicine Programs

Maggie L. Shaw
Despite the commonality of hypertension among US adults—nearly half of them have elevated blood pressure—hypertension education among internal residents has not kept up with the condition’s prevalence.
Image of an EKG flatline
November 11th 2022

PH, ILD Contribute to Higher Mortality Risks Among Patients With Systemic Sclerosis

Maggie L. Shaw
This investigation involved analyses of the potential for pulmonary hypertension (PH) and interstitial lung disease (ILD) to have an impact on patients living with systemic sclerosis.
Image of macitentan
November 3rd 2022

Macitentan Safety, Effectiveness in PAH Confirmed in New Analysis

Maggie L. Shaw
Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among patients with World Health Organizational functional class I-II disease.
An image of the kidneys and the heart
October 24th 2022

Potential Risk Factors Identified for RRT Among Patients With PH

Maggie L. Shaw
According to the study authors, acute decompensated pulmonary hypertension (PH) is often accompanied by systemic congestion and right ventricular flow output, and because PH can be accompanied by acute kidney injury, renal replacement therapy (RRT) may be necessary.
<123456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo